Diabetes Complications Clinical Trial
Official title:
Zoledronic Acid or Methylprednisolone in the Management of Active Charcot's Neuroarthropathy of Foot in Patients With Diabetes Mellitus: A Randomized, Double-blind, Placebo Controlled Trial
Charcot neuropathic osteoarthropathy (CNO) is a progressively destructive process resulting
from significant peripheral neuropathy of almost any aetiology. Diabetes mellitus has emerged
as the commonest cause of CNO.
The Charcot foot in diabetes poses many clinical challenges in its diagnosis and management.
The lacuna primarily lies in delineation of its etio-pathogenesis and consequently in
targeted treatment modalities. Although traditional approaches focus on neurotraumatic and
neurovascular theories, these fail to explain all the features of CNO, hence, other
hypotheses have been put forward.The current belief is that once the disease is triggered in
a susceptible individual, it is mediated through a process of uncontrolled inflammation
which, in turn, leads to osteolysis, fractures and joint destruction. Of these processes, the
involvement of the receptor activator of nuclear factor- кB (RANK) ligand
/RANK/osteoprotegerin (OPG) system in the process of acute CNO is particularly appealing and
suggests new pharmacological approaches.
Standard modalities of treatment include offloading and casting. Although various trials have
analysed the impact of medical agents including bisphosphonates, teriparatide and bone
stimulation techniques, the results have been either inconclusive or not translated into
clinical practice. Hence, there is no efficacious treatment of active CNO apart from the
traditional offloading. In view of recent advances in understanding of the disease process,
the target of intervention should, logically, be interruption of the inflammatory cascade and
subsequent osteoclast resorption. Zoledronic acid is the most potent bisphosphonate that has
been studied in clinical trials to date and has the distinctive profile of strong inhibitory
activity on the enzyme farnesyl pyrophosphate synthase, essential for osteoclast function.
Methylprednisolone conceivably has a potential benefit by offsetting the RANKL/OPG system
involved. There have been conflicting reports with bisphophosphonates in active CNO and
Zoledronic acid has been infrequently used despite being the most potent. Glucocorticoids
including methylprednisolone have also not been systematically tried in this condition.
We hypothesise that targeting the inflammatory cascade with Methylprednisolone and osteoclast
mediated damage by Zoledronic acid will address the basic etiopathogenesis of active CNO and
may result in earlier resolution of the disease activity. The above mentioned hypothesis is
hence, planned to be tested in a randomised, double-blind, placebo-controlled study.
Charcot's neuroarthropathy has been identified since 1883, yet we have much to learn about
the pathophysiology and evidence based treatment options. Active CNO is characterised by
repetitive trauma leading to inflammation in an insensate foot. This includes polypeptide
receptor activator of nuclear factor-kB ligand (RANKL) which triggers the synthesis of the
nuclear transcription factor nuclear factor-kb (NF-kb), and this in turn stimulates the
maturation of osteoclasts from osteoclast precursor cells. At the same time, NF-kb stimulates
the production of the glycopeptide osteoprotegerin (OPG) from osteoblasts. This "decoy
receptor" acts as an effective antagonist of RANKL . It has been suggested that this results
in continual production of proinflammatory cytokines, RANKL, NF-kb, and osteoclasts, which in
turn leads to continuing local osteolysis .This has adequately demonstrated by an increase in
proinflammatory phenotypes of monocytes in those with active Charcot foot when compared with
diabetic control subjects. Also osteoclasts generated in vitro in the presence of macrophage
colony-stimulating factor and RANKL from patients with active CN have been shown to be more
aggressive and exhibit an increase in their resorptive activity compared with control
subjects. Motor neuropathy contributes to altered structure of the foot with resultant
abnormal loading. Finally, it is possible that peptides like calcitonin gene-related peptide
(CGRP) , which normally antagonizes the synthesis of RANKL, reduced due to neuropathy
increase the RANKL expression. Diabetes may predispose to occurrence of CNO through a number
of mechanisms. Apart from the presence of neuropathy and possible osteopenia, these include
the effects of advanced glycation end products, reactive oxygen species, and oxidized lipids,
which may all enhance the expression of RANKL in diabetes.
The average delay in the diagnosis of acute Charcot has been reported to be around 29 weeks.
Common misdiagnoses include cellulitis, erysipelas, deep vein thrombosis (DVT), venous
insufficiency, gout, pseudogout, acute inflammatory arthritis, fracture, sprain, tumor,
septic arthritis, osteomyelitis, Sudeck's atrophy, and rheumatoid arthritis. Delay in prompt
diagnosis and initiation of treatment results in progression of the pathology resulting in
rigid osseous deformity of the foot increasing the risk of callus formation, ulceration,
infection, and lower extremity amputation by 15- to 40-fold .With the propensity for
misdiagnosis and high potential for progression to a rigid foot deformity, early recognition
and prompt initiation of treatment is paramount.
Radiographs are the primary initial imaging method for evaluation of the foot in suspected
CNO. However, they may initially be normal or show subtle fractures and dislocations.
Magnetic resonance imaging (MRI) has a higher sensitivity that allows detection of subtle
changes in the early stages of active CNO when X-rays could still be normal. MRI primarily
images protons in fat and water and can depict anatomy and pathology in both soft tissue and
bone in great detail because of its unique capability of differentiating tissues with high
detail.
Treatment of CNO is aimed at offloading the foot, treating bone disease, and preventing
further foot fractures. Because of the various etiologies of increased local bone resorption
and/or secondary osteoporosis in patients with CNO and limited randomized placebo-controlled
trials in this area, treatment guidelines are largely based on professional opinion rather
than the highest level of clinical evidence. Hence, there remains a dearth of evidence based
medical management for Charcot neuroarthropathy. Offloading at the acute active stage of the
Charcot foot is the most important management strategy and could arrest the progression to
deformity. Ideally, the foot should be immobilized in an irremovable total contact cast
(TCC), which is initially replaced at 3 days, then checked each week. Edema reduction is
often remarkable in the first few weeks of treatment. The cast should be changed frequently
to avoid "pistoning" as the edema subsides.
However, It is important to take into consideration that TCC may actually have unfavorable
consequences including unnatural stress patterns, increased instability, loss of muscle tone,
proprioception and boe density.Also, they are not designed to affect the underlying
physiological mechanisms that cause bone destruction.In this context, treatment by
antiresorptive drugs emerges as an attractive option. Bone turnover in patients with active
CNO is excessive, hence bisphosphonates, by inhibiting osteoclast mediated resorption, have
an important role to play. However, there is little evidence to support their use at
present.Both oral and intravenous bisphosphonates have been studied in the treatment of CNO
in small randomized, double-blind, controlled trials or in retrospective controlled studies.
Whatever the precise pathophysiological mechanism of CNO, bone resorption and osteoclastic
hyperactivity is a major feature of the early acute stage of this condition and makes the use
of bone-resorption-inhibiting agents such as bisphosphonates(BPs) a logical therapeutic
approach. Theoretically, pharmacological treatment of CNO by BPs, which inhibit osteoclastic
resorption and may have direct anti-inflammatory properties, might slow or even stop the bony
destruction through its ability to cause macrophage apoptosis.
Selby et al first reported the use of a BP in the treatment of CNO. They administered 30 mg
pamidronate i.v.,followed by five infusions of pamidronate 60 mg every 2 weeks for 12 weeks
in six patients with diabetes and acute CNO. The treatment was associated with improvement in
local pain and a significant reduction in the activity of the CNO as measured by the decrease
in the temperature of the affected foot, from 3.4±0.7°C (mean±SE) to 1.0±0.5°C (p 0.05).
There was also a significant reduction in bone turnover as judged by alkaline phosphatase
(ALP) level, which fell by 25±3% compared with initial values (p<0.001). Stansberry et al in
1999 reported a decrease in peak cutaneous blood flow in response to the infusion of 90 mg
pamidronate i.v. over 24 h in 20 patients with diabetes and CNO, suggesting a
anti-inflammatory action of pamidronate. In 1999, Young reported anecdotally two cases of
diabetic acute CNO treated with i.v. infusions of pamidronate associated with immobilisation.
After 3 months, the clinical outcome was judged favourable with a reduction in clinical signs
and an absence of deformity. Pakarinen et al. in 2002 retrospectively analysed clinical
records and X-rays of 36 feet with CNO from 1994 to 2000. Eighteen patients received BPP
treatment (pamidronate 30-60 mg i.v. once a week for 6 weeks) and no complications were
registered. There was no statistically significant difference in casting time between
patients who received (11 weeks) and patients who did not receive (13 weeks) pamidronate. In
this series, pamidronate infusions were used for selected individuals without any striking
benefits or disadvantages. Clinically, treatment with BP was associated with a more rapid
decrease in skin temperature, but this effect was not sustained. Effect on the pain differed
among studies, with one showing improvement but another showing none.Pakarinen et al tried
Zoledronic acid and reported that it did not reduce the duration of immobilization. Rather
there was an increase in total time for casting in subjects treated with Zoledronic
acid.Similar observations about longer time of immobilization with the use of BPs was
reported in the the recent multicentric observational audit of acute diabetic CNO in the UK.
Randomised trials looking into possible use of glucocorticoids in management of active CNO
have not been undertaken, possibly because of only recent understanding of the role of acute
inflammation triggering the osteolysis that characterizes CNO. Intravenous
supra-pharmacological doses of corticosteroids have been used in various inflammatory and
autoimmune conditions because they are cumulatively less toxic than sustained steroid
treatment at lower quantitative dosage. Their action is supposed to be mediated through
non-genomic actions within the cell. When corticosteroids are administered as pulses, an
immediate profound anti-inflammatory effect is achieved, inflammatory damage is minimized ,
toxicity is low and there is no prolonged suppressive effect on the hypothalamic-pituitary
axis. But there are no randomized trials looking into the efficacy and potential benefit of
methylprednisolone in CNO as of date.
Hence this trial was designed to compare the therapeutic efficacy and profiles of two well
known agents Zoledronic acid (antiresorptive) and Methylprednisolone (anti-inflammatory) in
patients of diabetes mellitus with active CNO of foot.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03022721 -
Heidelberg Study on Diabetes and Complications
|
N/A | |
Withdrawn |
NCT02580266 -
Blood/Urine Markers for Drug Discovery for Renal Disease in Diabetes
|
||
Completed |
NCT02423434 -
Evaluation of Corneal Confocal Microscopy for the Identification and Prediction of Neuropathy in Type 1 Diabetes
|
||
Completed |
NCT01695278 -
A Pilot Intervention Study of Health Coaching to Promote Diabetes Self-Care in the Community
|
Phase 3 | |
Completed |
NCT03426566 -
Abnormal Plantar Pressure in Patients With Diabetes
|
||
Completed |
NCT02588898 -
B-Vitamins and Polyneuropathy in Patients With Type 2 Diabetes
|
||
Completed |
NCT00815178 -
Effects of Inspiratory Muscle Training on Type 2 Diabetes Mellitus Patients With Inspiratory Muscle Weakness
|
N/A | |
Not yet recruiting |
NCT04537676 -
Patient Empowerment Study
|
||
Terminated |
NCT02915263 -
The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes
|
Phase 2 | |
Completed |
NCT01929018 -
Collaborative-care Rehabilitation After Dysvascular Amputation
|
N/A | |
Completed |
NCT03877523 -
Cocarnit Effects on Macrophages Polarization
|
N/A | |
Completed |
NCT02928939 -
Therapeutic Conflicts and Multimorbidity
|
||
Completed |
NCT02947828 -
Polyneuropathy in Diabetes Mellitus Type 2
|
||
Recruiting |
NCT02275091 -
Children With Diabetes at Risk for Heart Disease.
|
||
Terminated |
NCT00529204 -
Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease
|
Phase 2 | |
Not yet recruiting |
NCT05074849 -
Benefits of Insoles With Real-Time Alert and Foot Self-Care Education
|
N/A | |
Completed |
NCT04963998 -
Safety and Efficacy Study of MedCu Wound Dressings
|
N/A | |
Recruiting |
NCT06321029 -
Electronic Diabetes Tune-Up Group (eDTU) for African Americans
|
N/A | |
Active, not recruiting |
NCT03620773 -
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT05231642 -
Individualised Postprandial Glucose Responses in Type 1 Diabetes
|
N/A |